Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.
about
Chimeric receptors of the human C3a receptor and C5a receptor (CD88)Switch moiety in agonist/antagonist dual effect of S19 ribosomal protein dimer on leukocyte chemotactic C5a receptorIdentification of receptor-binding sites of monocyte chemotactic S19 ribosomal protein dimerHeterologous quaternary structure of CXCL12 and its relationship to the CC chemokine familyStructural and functional characterization of human and murine C5a anaphylatoxinsStructural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopyIdentification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxinRoles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytesThe promiscuous chemokine binding profile of the Duffy antigen/receptor for chemokines is primarily localized to sequences in the amino-terminal domainA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon bindingC5a receptor activation. Genetic identification of critical residues in four transmembrane helices.Genetic mapping of the human C5a receptor. Identification of transmembrane amino acids critical for receptor function.A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.An activation switch in the ligand binding pocket of the C5a receptor.Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking.An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling.Identification of CXCR4 domains that support coreceptor and chemokine receptor functionsMapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis.Molecular mechanism of monocyte predominant infiltration in chronic inflammation: mediation by a novel monocyte chemotactic factor, S19 ribosomal protein dimer.Identification of a potent and orally active non-peptide C5a receptor antagonist.Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1.Complement System Part I - Molecular Mechanisms of Activation and Regulation.The role of the anaphylatoxins in health and disease.Pharmacological characterization of antagonists of the C5a receptorProteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis.Organization and functions of interacting domains for signaling by protein-protein interactions.Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activityTwo distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.Novel C5a regulators in inflammatory disease.Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent.The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome.A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer.Soluble complexes of regulated upon activation, normal T cells expressed and secreted (RANTES) and glycosaminoglycans suppress HIV-1 infection but do not induce Ca(2+) signaling.Rational design of novel HIV-1 entry inhibitors by RANTES engineeringThe differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors
P2860
Q22009065-415DE74C-D94D-4297-A058-03A9D29EAB35Q24684191-9BD89C70-DA26-4621-8412-20FBDB86020BQ24685662-849466FD-DCF3-46B0-AC0D-346F15459EAFQ27658969-EE1CA58A-0E04-4406-A53E-5F279B287D46Q27684270-4E4C78F4-AD85-47D5-A530-4416DCF7C401Q27739356-A067D2DC-5139-44D3-B313-03DFE1C2B49DQ28262686-04034351-2CE8-4D06-B1DE-F31743A64527Q28268382-E559C510-4E34-4144-AC05-3752C0DA37BEQ28281482-06DAF90E-F85B-4FB4-8BAB-1649413F419DQ28291871-3FE8249D-5A7C-4B3C-B12C-A4FC370E0BC5Q28344177-79105141-7803-4575-B513-068F063FB227Q28581696-7D2BEEA0-32E2-4292-884D-276DE8751B79Q30636240-951D53FC-F00A-462E-95AC-09EDD30A70E1Q30909039-163C920E-0163-4A54-863B-3325260BB485Q31395542-7E40FA9D-5D73-4634-BB3B-815BA81A1B94Q31524077-86C177E1-F0C2-4A7F-B4E0-F3C6C47F1E9FQ33259490-63A9CFEC-E3B4-478D-B399-FF65F755FD1AQ33307183-CD429302-2C82-426A-8D0A-1F94F6C1BAE4Q33314698-A4E0E7D4-B79A-402C-B4D2-CABA222BA135Q33643223-5E14C98B-3904-4633-972E-3B10AC1D7A73Q34067117-AA39E255-8537-4044-988F-035917E7CE4BQ34099140-D899F92B-111B-4733-B5D7-26DA5C794398Q34154819-07132EF3-EB12-43AD-9EBF-4B37DA7F3A96Q34447967-95814E2D-E0B1-4B76-AB43-94143833B51DQ34481071-36E3D512-863E-4034-9AE5-4E30C8CA4B4EQ34983578-4C6BDCC1-A57E-42E9-9B87-2AA45FC12B2BQ35041753-309ABC16-A473-40A1-A5CC-F782D9EA8D84Q35495294-B87D185C-84F3-40CC-9512-19C1A92BEB46Q35587760-F3B2F344-8470-4B16-A11C-3D9707FD7058Q35745595-8075C41D-CD04-4975-9F3F-6CCFE08AAE8FQ35890885-41C820BE-C0E5-4230-B5E1-F46310934E3EQ36196446-744E9C67-39C7-4F3A-8C0E-833CED2BDEAEQ36334083-5A2A169E-9182-429A-8F5C-FEF50866FC39Q36369323-3D7C375C-F7D5-4361-9FCA-2108C0C9E022Q36403878-A593CB6A-AE0F-40C1-944C-6D4DFA35BABCQ36533660-4CE97703-D340-4312-BA82-283E7CDDC9EBQ36554378-D2D96AF3-064B-4D8A-A46F-28851B56596FQ36746649-D53C470D-4C5B-4634-B136-06117443C4ECQ36793736-5DF0A333-5CFC-48FB-A8B7-91D3B56D6520Q37092774-AADFB9D1-9EEE-4F8F-B086-17C1D420684B
P2860
Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.
description
1994 nî lūn-bûn
@nan
1994 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@ast
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@en
type
label
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@ast
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@en
prefLabel
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@ast
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@en
P2093
P2860
P356
P1476
Two-site binding of C5a by its ...... r G protein-coupled receptors.
@en
P2093
DeMartino J
Konteatis Z
Malkowitz L
Rollins TE
Siciliano SJ
Springer MS
Van Riper G
P2860
P304
P356
10.1073/PNAS.91.4.1214
P407
P577
1994-02-01T00:00:00Z